Medicare Advantage members would stay for their doctors, not a lower price: 12 of 23 name keeping their providers
Asked what would most keep them with their insurer if their plan ended, 12 of 23 US Medicare Advantage members on the panel named keeping their own doctors and 2 named lower costs, September 2026.
- Who was asked
- US Medicare Advantage members, 200 clones, US
- When
- September 2026 (fielded 26 September 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question is which benefits win at open enrollment. This asked instead what a member would do when the choice is forced on them by their own plan ending, because that is the moment a switch actually happens.
Section 01: What the panel said
- #
12
For the Medicare Advantage members on this panel, keeping their own doctors is the one thing that would hold them to their insurer.
base 23
- #
20
Continuity is the default: almost every Medicare Advantage member on the panel would take the replacement plan their insurer offers rather than shop.
base 22
- #
43.5%
Off the Medicare Advantage base the ranking reverses: among the panellists not on such a plan, lower costs leads at 43.5%.
base 177 · contrast
- #
12
Among the Medicare Advantage members, keeping their doctors is named more often than costs, trust, coverage and service put together.
base 23
Among the Medicare Advantage members, keeping their doctors is named more often than costs, trust, coverage and service put together.
02What is the first thing a plan should take from this?
When a health plan ends, the people who are actually on one do not reach for the price first. Asked what would most keep them with their insurer, 12 of the 23 Medicare Advantage members on this panel named keeping their own doctors. Two named lower costs.
That order matters because a replacement offer is usually written around the premium and the out-of-pocket maximum. On this evidence the first thing a member wants to know is whether their own doctors and hospital are still in the network.
03Where does the answer change, and for whom?
It reverses completely off that base. Among the 177 panellists who are not on a Medicare Advantage plan, lower costs led at 43.5% and keeping doctors followed at 30.5%. The same question, the same fielding, the opposite ranking.
The wider panel is answering about a plan they do not hold, which is exactly why the headline number a study like this produces can point the wrong way. Cost is what people say about insurance in the abstract. Doctors are what they say when the plan is their own.
04What would a retention team do with this?
- Lead the replacement offer with the network, not the premium. This is a reading of a small base, not the panel's instruction: 23 clones answered, so it is a signal to test rather than a settled number.
- Treat staying as the default and protect it. Of the Medicare Advantage members asked, 20 of 22 would take the replacement plan their insurer offers rather than shop, though that option was the status quo and was named first, so some of it is inertia rather than loyalty.
- Watch the small group that would leave. Two of the 22 would move to a rival plan and none chose Original Medicare with a Medigap policy, which suggests the risk at a forced re-shop is losing people to another plan of the same kind.
Section 05: What they said, and the interview line it rests on
“My oncologist, my primary care physician and the hospital clinic system know my history inside and out. That continuity of care is vital to my life. If our plan were discontinued and we had to pick another plan from the same insurer, making sure I do not lose access to those doctors would be the deciding factor.”
Predicted from this line in the interview
“It's specific to the hospital and medical clinic system that we utilize all of the time. So our providers that we are familiar with and comfortable with are always covered in the plan.”
Section 06: How much should you trust this?
What we would defend
- The ranking inside the Medicare Advantage group: doctors first, cost near the bottom.
- The direction of the gap between the two groups, which is large and identical across both pulls of the data.
What we would not
- Any percentage for Medicare Advantage members, because the base is under 30.
- The 20 of 22 read as a retention rate: the insurer's own plan was the status quo option and was named first in the question.
- A 65 plus reading, because age could not be cut independently of enrollment.
The main limitation
Only 82 of 779 panellists screened were on a Medicare Advantage plan and 23 of them answered the retention question, so every Medicare Advantage figure here is a count on a small base.
Section 07: How was this run?
| Segment | Clones |
|---|---|
| On a Medicare Advantage plan | 23 |
| Not on a Medicare Advantage plan | 177 |
Question wording as fielded
- Are you currently enrolled in a Medicare Advantage plan?
- If the Medicare Advantage plan you are on were discontinued for next year and you had to choose again during open enrolment, would you take the replacement plan your current insurer offers you, move to a different insurer's Medicare Advantage plan, or go back to Original Medicare with a Medigap policy?
- What would most make you stay with your current insurer?
What was not asked, and why
Nobody was asked to compare named insurers or named plans, and nobody was given premiums in dollars, so this shows what people reach for first, not what they would pay.
What changed from the obvious question
The obvious question is which benefits win at open enrollment. This asked instead what a member would do when the choice is forced on them by their own plan ending, because that is the moment a switch actually happens.
Fielded through Ask Brox on 26 September 2026.
More on Switching treatment or staying put · Pharma & HCP · Healthcare (US) panel
Related insights
All in this topic-
Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points
58.6% 58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60. (base 169)
Read -
Insurance, not clinical doubt, is what holds back 66.1% of US dermatologists from moving moderate eczema patients off topicals and onto a systemic
66.1% 66.1% of US dermatologists say insurance requirements or prior authorization are what most often make them hold off moving an adult with moderate eczema from topicals to a systemic (base 127)
Read -
Biosimilar substitution: 94.5% of US clinicians, mostly dermatologists, accept a switch they choose, but half object when a pharmacy swaps without contacting them
50% 50.0% of physicians who manage biologics are uncomfortable (1 or 2 of 5) with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them first, against 2.7% when they choose the switch and 20.5% when an insurer requires it. (base 146)
Read -
Fear of side effects, not cost, keeps 53.6% of US migraine sufferers on the treatment they have
53.6% 53.6% of US migraine sufferers say worry about the side effects of something new is what would most keep them on their current treatment if a new one were available; 31.8% say what they have works well enough, 6.4% say their doctor has not suggested changing, 4.5% would switch as soon as something better appeared and 3.6% are unsure what a new drug would cost or whether insurance would cover it. (base 110)
Read